276 related articles for article (PubMed ID: 21777949)
61. Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence.
Hu Z; Mudaliar K; Quek ML; Paner GP; Barkan GA
Ann Diagn Pathol; 2014 Apr; 18(2):49-52. PubMed ID: 24370460
[TBL] [Abstract][Full Text] [Related]
62. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.
Boorjian SA; Zhu F; Herr HW
BJU Int; 2010 Aug; 106(3):357-61. PubMed ID: 20002665
[TBL] [Abstract][Full Text] [Related]
63. Bladder cancer: clinical and pathological profile.
Lopez-Beltran A
Scand J Urol Nephrol Suppl; 2008 Sep; (218):95-109. PubMed ID: 18815924
[TBL] [Abstract][Full Text] [Related]
64. Recurrence and progression in low grade papillary urothelial tumors.
Holmäng S; Hedelin H; Anderström C; Holmberg E; Busch C; Johansson SL
J Urol; 1999 Sep; 162(3 Pt 1):702-7. PubMed ID: 10458347
[TBL] [Abstract][Full Text] [Related]
65. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy.
Holmäng S; Andius P; Hedelin H; Wester K; Busch C; Johansson SL
J Urol; 2001 Apr; 165(4):1124-8; discussion 1128-30. PubMed ID: 11257652
[TBL] [Abstract][Full Text] [Related]
66. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.
Cho KS; Seo HK; Joung JY; Park WS; Ro JY; Han KS; Chung J; Lee KH
J Urol; 2009 Dec; 182(6):2625-30. PubMed ID: 19836779
[TBL] [Abstract][Full Text] [Related]
67. Percutaneous management of renal pelvic urothelial tumors: long-term followup.
Goel MC; Mahendra V; Roberts JG
J Urol; 2003 Mar; 169(3):925-9; discussion 929-30. PubMed ID: 12576814
[TBL] [Abstract][Full Text] [Related]
68. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors.
Palou J; Rodríguez-Rubio F; Millán F; Algaba F; Rodríguez-Faba O; Huguet J; Villavicencio H
Urology; 2009 Jun; 73(6):1313-7. PubMed ID: 19362341
[TBL] [Abstract][Full Text] [Related]
69. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
70. Urothelial papilloma of the bladder: a review of 34 de novo cases.
Magi-Galluzzi C; Epstein JI
Am J Surg Pathol; 2004 Dec; 28(12):1615-20. PubMed ID: 15577681
[TBL] [Abstract][Full Text] [Related]
71. Long term outcome of primary urothelial papilloma: a single institution cohort.
Al Bashir S; Yilmaz A; Gotto G; Trpkov K
Pathology; 2014 Jan; 46(1):37-40. PubMed ID: 24300727
[TBL] [Abstract][Full Text] [Related]
72. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
[TBL] [Abstract][Full Text] [Related]
73. Urothelial tumors of the urinary bladder in young patients: a clinicopathologic study of 59 cases.
Stanton ML; Xiao L; Czerniak BA; Guo CC
Arch Pathol Lab Med; 2013 Oct; 137(10):1337-41. PubMed ID: 24079760
[TBL] [Abstract][Full Text] [Related]
74. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder.
Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Navone R
Am J Surg Pathol; 2001 Dec; 25(12):1528-33. PubMed ID: 11717543
[TBL] [Abstract][Full Text] [Related]
75. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification.
Santos L; Amaro T; Costa C; Pereira S; Bento MJ; Lopes P; Oliveira J; Criado B; Lopes C
Int J Cancer; 2003 Jun; 105(2):267-72. PubMed ID: 12673690
[TBL] [Abstract][Full Text] [Related]
76. CD 10 expression intensity in various grades and stages of urothelial carcinoma of urinary bladder.
Atique M; Abbasi MS; Jamal S; Khadim MT; Akhtar F; Jamal N
J Coll Physicians Surg Pak; 2014 May; 24(5):351-5. PubMed ID: 24848395
[TBL] [Abstract][Full Text] [Related]
77. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma.
Hartmann A; Moser K; Kriegmair M; Hofstetter A; Hofstaedter F; Knuechel R
Am J Pathol; 1999 Mar; 154(3):721-7. PubMed ID: 10079249
[TBL] [Abstract][Full Text] [Related]
78. Expectant management of small, recurrent, noninvasive papillary bladder tumors.
Soloway MS; Bruck DS; Kim SS
J Urol; 2003 Aug; 170(2 Pt 1):438-41. PubMed ID: 12853794
[TBL] [Abstract][Full Text] [Related]
79. Bladder urothelial neoplasms in pediatric age: experience at three tertiary centers.
Berrettini A; Castagnetti M; Salerno A; Nappo SG; Manzoni G; Rigamonti W; Caione P
J Pediatr Urol; 2015 Feb; 11(1):26.e1-5. PubMed ID: 25305695
[TBL] [Abstract][Full Text] [Related]
80. Urothelial dysplasia of the bladder: diagnostic features and clinical significance.
Lopez-Beltran A; Montironi R; Vidal A; Scarpelli M; Cheng L
Anal Quant Cytopathol Histpathol; 2013 Jun; 35(3):121-9. PubMed ID: 24344498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
